Replacement of mycophenolate mofetil, cyclosporine, or tacrolimus by sirolimus results in regression of Kaposi's sarcoma (KS) in organ transplant recipients.1-3 In these patients, clearance from KS might result either from reduced immunosuppression or from the direct antiangiogenic effects of sirolimus.
Guenova E, Metzler G, Hoetzenecker W, Berneburg M, Rocken M. Classic Mediterranean Kaposi’s Sarcoma Regression With Sirolimus Treatment. Arch Dermatol. 2008;144(5):692–693. doi:10.1001/archderm.144.5.692
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: